Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.49 |
| ▸ | KDM4A | O75164 | 1/20 | 0.49 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.49 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.49 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.45 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17506460 | 1.00 | TSHR (0.58) | TSHRL3MBTL1LMNAALDH1A1KDM4C | |
| SCHEMBL19281392 | 1.00 | TSHR (0.58) | TSHRL3MBTL1LMNAALDH1A1KDM4C | |
| SCHEMBL1369686 | 1.00 | TSHR (0.58) | TSHRL3MBTL1LMNAALDH1A1KDM4C | |
| SCHEMBL19281389 | 1.00 | TSHR (0.58) | TSHRL3MBTL1LMNAALDH1A1KDM4C | |
| SCHEMBL19281387 | 1.00 | TSHR (0.58) | TSHRL3MBTL1LMNAALDH1A1KDM4C | |
| SCHEMBL5056126 | 1.00 | TSHR (0.58) | TSHRL3MBTL1LMNAALDH1A1KDM4C | |
| SCHEMBL2254699 | 1.00 | TSHR (0.58) | TSHRL3MBTL1LMNAALDH1A1KDM4C | |
| SCHEMBL19281377 | 1.00 | TSHR (0.58) | TSHRL3MBTL1LMNAALDH1A1KDM4C | |
| SCHEMBL2345504 | 1.00 | TSHR (0.58) | TSHRL3MBTL1LMNAALDH1A1KDM4C | |
| SCHEMBL19281385 | 1.00 | TSHR (0.58) | TSHRL3MBTL1LMNAALDH1A1KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240084343-A1 | METHODS OF USING NATURAL AND ENGINEERED ORGANISMS TO PRODUCE SMALL MOLECULES FOR INDUSTRIAL APPLICATION | KIVERDI INC (US) | 2024-03-14 | — | — | US | disclosed |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2023-04-27 | — | — | US | disclosed |
| CN-111187161-B | Preparation method of dihydrocapsaicin and dihydrocapsaicin ester | 中国科学技术大学 | 2021-10-01 | — | — | CN | disclosed |
| US-20210115481-A1 | Methods of Using Natural and Engineered Organisms to Produce Small Molecules for Industrial Application | KIVERDI INC (US) | 2021-04-22 | — | — | US | disclosed |
| CN-111187161-A | Preparation method of dihydrocapsaicin and dihydrocapsaicin ester | 中国科学技术大学 | 2020-05-22 | — | — | CN | disclosed |
| US-20180201572-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2018-07-19 | — | — | US | disclosed |
| US-9868692-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868693-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9867888-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868691-B2 | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| WO-2014145194-A2 | METHODS OF USING NATURAL AND ENGINEERED ORGANISMS TO PRODUCE SMALL MOLECULES FOR INDUSTRIAL APPLICATION | KIVERDI, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20130288992-A1 | GLYCOSIDE COMPOUND | PEPPER REVOLUTION COMPANY LLC (JP) | 2013-10-31 | — | — | US | disclosed |
| EP-2657244-A1 | GLYCOSIDE COMPOUND | Ajinomoto Co., Inc. (JP) | 2013-10-30 | — | — | EP | disclosed |
| US-8183280-B2 | FAP inhibitors | VANTIA LIMITED (GB) | 2012-05-22 | — | — | US | disclosed |
| US-7994152-B2 | Method of treating a cancer by administering A 2′,5′-oligoadenylate analog | SANKYO COMPANY, LIMITED (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20100081701-A1 | FAP inhibitors | VANTIA LIMITED (GB) | 2010-04-01 | — | — | US | disclosed |
| US-20100035976-A1 | Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog | SANKYO COMPANY, LIMITED (JP) | 2010-02-11 | — | — | US | disclosed |
| US-7651999-B2 | phosphorothioate modification containg oligonadenylates useful as antiviral, anticarcinogenic and antitumor agent; stable and have superior activity for treating lung cancer | SANKYO COMPANY, LIMITED (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20050261235-A1 | 2' ,5' -Oligoadenylate analogs | SANKYO COMPANY, LIMITED (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1568704-A1 | NOVEL 2' ,5' -OLIGOADENYLIC ACID ANALOGUES | Sankyo Company, Limited (JP) | 2005-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261235-A1 | 2' ,5' -Oligoadenylate analogs | NSUN2, RNGTT, NSUN3 | TSHR 1870/4885L3MBTL1 43/4885LMNA 2237/4885 |
| US-20100081701-A1 | FAP inhibitors | FAP, APC, SERPINB1 | TSHR 3886/4885L3MBTL1 3583/4885LMNA 2975/4885 |
| US-20130288992-A1 | GLYCOSIDE COMPOUND | GLP1R, GCG, NPY4R | TSHR 908/4885L3MBTL1 1386/4885LMNA 3359/4885 |
| US-20100035976-A1 | Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog | ADAR, NSUN2, ADORA3 | TSHR 1214/4885L3MBTL1 179/4885LMNA 2298/4885 |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | HMOX1, CD209, HMOX2 | TSHR 1695/4885L3MBTL1 1986/4885LMNA 4039/4885 |
| US-20180201572-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PLTP, PLIN3 | TSHR 3089/4885L3MBTL1 869/4885LMNA 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.